Protein aggregation diseases: pathogenicity and therapeutic perspectives

@article{Aguzzi2010ProteinAD,
  title={Protein aggregation diseases: pathogenicity and therapeutic perspectives},
  author={A. Aguzzi and Tracy O'Connor},
  journal={Nature Reviews Drug Discovery},
  year={2010},
  volume={9},
  pages={237-248}
}
A growing number of diseases seem to be associated with inappropriate deposition of protein aggregates. Some of these diseases — such as Alzheimer's disease and systemic amyloidoses — have been recognized for a long time. However, it is now clear that ordered aggregation of pathogenic proteins does not only occur in the extracellular space, but in the cytoplasm and nucleus as well, indicating that many other diseases may also qualify as amyloidoses. The common structural and pathogenic features… Expand
Chemical kinetics for drug discovery to combat protein aggregation diseases.
Dynamic droplets: the role of cytoplasmic inclusions in stress, function, and disease
Functional diversity of protein fibrillar aggregates from physiology to RNA granules to neurodegenerative diseases.
Biophysical Aspects of Alzheimer’s Disease: Implications for Pharmaceutical Sciences
  • P. Arosio
  • Chemistry, Medicine
  • Pharmaceutical Research
  • 2017
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 191 REFERENCES
Conformation-dependent anti-amyloid oligomer antibodies.
Therapeutic Strategies for Alzheimer’s Disease
Aggregation Propensity of the Human Proteome
Aspects on human amyloid forms and their fibril polypeptides
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Molecular mechanisms of prion pathogenesis.
...
1
2
3
4
5
...